The fact that Russia approved a flu drug without efficacy data for COVID-19 is lame and hardly relevant for us. Even if the trials confirm its efficacy, the benefit will likely be modest, just like with remdesivir and won't work against the cytokine storm in severe cases.... With an end of June - mid-July readout we are still very well positioned provided the results are truly excellent.